This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Arranz M et al (2001) Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenom 1(1): 3–10
Basile VS et al (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5: 410–417
Basile VS et al (2001) Genetic association of atypical antipsychotic-induced weight gain. Novel preliminary data on the pharmacogenetic puzzle. J Clin Psychol 62: 45–66
Boulton DW et al (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychoticset al. Life Sci 71(2): 163–169
Davies MA et al (2004) The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drzgs: is M(1) agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacol 178(4): 451–460
Dose M (2000) Recognition and management of acute neuroloeptic-induced extrapyramidal motor and mental syndromes. Pharmacopsychiatry 33[Suppl 1]: 3–13
Eichhammer P et al (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathasia in schizophrenic patients: a generalization of Steen’s study on DRD3 and tardive dyskinesia. Am J Med Genet 96: 187–191
Griffon N et al (1996) Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 67: 63
Halliday G et al (1999) Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp Neurol 158: 155–163
Hoffmeyer S et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7): 3473–3478
Kalgutkar A et al (2003) Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioacitivation pathway. Drug Metab Dispos 31: 243–249
Kapitany T et al (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Mol Psychiatry 3: 337–341
Lerer B et al (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3-receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27: 105–119
Ma M et al (2002) Genetic basis of drug metabolism. Am J Health Syst Pharm 59(21): 2061–2069
Reznik I et al (2000) Genetic factors in clozapine-induced agranulocytosis. Isr Med Assoc J 2: 857–858
Schlicht K et al (2005) Comparative proteomic analysis with postmortem prefrontal cortex tissues of suicide victims versus controls. Biol Psych (submitted)
Scordo MG et al (2000) CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56: 679–83
Seeman P et al (1994) Dopamine receptor pharmacology. TIPS 15: 264–270
Silverman JA et al (1999) Multidrug-resistance transporters. Pharm Biotechnol 12: 353–368
Stahl S (2002) Essential psychopharmacology, neuroscientific basis and practical applications. Cambridge University Press, Cambridge
Turbay D et al (1997) Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic group. Blood 89: 4167–4174
Usuki E et al (1996) Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 9(4): 800–806
van Tol H et al (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358: 149–152
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag/Wien
About this paper
Cite this paper
Ackenheil, M. (2006). Die Rolle der Pharmakogenetik/-genomic für die Behandlung der Schizophrenie. In: Möller, HJ., Müller, N. (eds) Aktuelle Aspekte der Pathogenese und Therapie der Schizophrenie. Springer, Vienna. https://doi.org/10.1007/3-211-29109-1_9
Download citation
DOI: https://doi.org/10.1007/3-211-29109-1_9
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-29043-9
Online ISBN: 978-3-211-29109-2
eBook Packages: Medicine (German Language)